Oppenheimer Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a ...